10,900 Shares in ICU Medical, Inc. $ICUI Acquired by Louisiana State Employees Retirement System

Louisiana State Employees Retirement System bought a new position in shares of ICU Medical, Inc. (NASDAQ:ICUI) during the 1st quarter, according to its most recent 13F filing with the SEC. The firm bought 10,900 shares of the medical instruments supplier’s stock, valued at approximately $1,408,000.

A number of other institutional investors have also recently bought and sold shares of ICUI. AQR Capital Management LLC increased its position in shares of ICU Medical by 2.5% during the first quarter. AQR Capital Management LLC now owns 9,360 shares of the medical instruments supplier’s stock worth $1,297,000 after acquiring an additional 229 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in ICU Medical by 4.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,764 shares of the medical instruments supplier’s stock worth $1,772,000 after purchasing an additional 560 shares during the period. United Services Automobile Association acquired a new position in ICU Medical in the 1st quarter worth $218,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in ICU Medical by 32.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 68,211 shares of the medical instruments supplier’s stock worth $9,472,000 after purchasing an additional 16,680 shares in the last quarter. Finally, Intech Investment Management LLC increased its holdings in ICU Medical by 38.6% during the 1st quarter. Intech Investment Management LLC now owns 11,938 shares of the medical instruments supplier’s stock worth $1,658,000 after purchasing an additional 3,326 shares in the last quarter. Institutional investors own 96.10% of the company’s stock.

ICU Medical Stock Up 4.4%

Shares of ICUI stock opened at $154.97 on Friday. The firm’s fifty day moving average price is $133.16 and its two-hundred day moving average price is $138.47. The company has a current ratio of 2.34, a quick ratio of 1.17 and a debt-to-equity ratio of 0.60. ICU Medical, Inc. has a 1 year low of $107.00 and a 1 year high of $160.29. The firm has a market capitalization of $3.87 billion, a P/E ratio of 83.77, a PEG ratio of 2.08 and a beta of 0.76.

ICU Medical (NASDAQ:ICUI) last posted its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $1.97 EPS for the quarter, topping analysts’ consensus estimates of $1.78 by $0.19. The company had revenue of $525.77 million during the quarter, compared to the consensus estimate of $520.65 million. ICU Medical had a net margin of 2.15% and a return on equity of 7.50%. The company’s quarterly revenue was down 12.3% on a year-over-year basis. During the same period in the prior year, the business posted $1.72 EPS. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. On average, equities analysts predict that ICU Medical, Inc. will post 6.5 EPS for the current fiscal year.

Insider Activity at ICU Medical

In other ICU Medical news, VP Virginia Ruth Sanzone sold 2,447 shares of the firm’s stock in a transaction that occurred on Thursday, May 14th. The stock was sold at an average price of $124.08, for a total value of $303,623.76. Following the completion of the transaction, the vice president directly owned 19,460 shares in the company, valued at $2,414,596.80. This trade represents a 11.17% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director David C. Greenberg sold 2,424 shares of the firm’s stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $122.91, for a total value of $297,933.84. Following the completion of the transaction, the director owned 7,960 shares of the company’s stock, valued at approximately $978,363.60. This represents a 23.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Corporate insiders own 2.10% of the company’s stock.

Analysts Set New Price Targets

ICUI has been the topic of several recent research reports. BTIG Research initiated coverage on ICU Medical in a research note on Monday, June 15th. They issued a “buy” rating and a $170.00 price target on the stock. Piper Sandler decreased their price objective on ICU Medical from $178.00 to $163.00 and set an “overweight” rating for the company in a report on Friday, April 17th. Weiss Ratings raised ICU Medical from a “sell (d)” rating to a “sell (d+)” rating in a research report on Monday, May 11th. KeyCorp dropped their target price on ICU Medical from $180.00 to $164.00 and set an “overweight” rating on the stock in a research report on Monday, April 27th. Finally, Zacks Research raised ICU Medical from a “hold” rating to a “strong-buy” rating in a research report on Monday. Three analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $168.40.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.